FDA Brief

Warning letters Devices

FDA warning letter to

Smiths Medical ASD Inc.

High riskIssued Oct 1, 2021Posted Nov 23, 2021Center for Devices and Radiological Health

FDA cites Smiths Medical for unreported Medfusion pump malfunctions and quality-system failures at its Minneapolis facility.

What happened

FDA inspected Smiths Medical ASD's medical device operations in Minneapolis from February 23 to March 30, 2021, with amended inspection observations signed May 28, 2021. FDA found the firm did not submit required medical device reports for Medfusion syringe pump malfunctions, including unexpected battery depletion, and did not report a correction or removal for a supercapacitor replacement. FDA also found Quality System violations in design validation, corrective and preventive action, complaint handling, and design history records.

What FDA found

  1. Smiths Medical did not submit a 30-day medical device report after learning that Medfusion syringe pumps malfunctioned, including unexpected battery depletion.

    21 CFR 803.50(a)(2)
  2. Smiths Medical did not send FDA a written report about a correction or removal for a supercapacitor replacement in Medfusion 3500 and 4000 pumps.

    21 CFR 806.10
  3. Smiths Medical did not establish and maintain adequate design validation, including validation of software and firmware combinations and a power cord retainer change.

    21 CFR 820.30(g)
  4. Smiths Medical's corrective and preventive action procedure was inadequate, and CAPAs did not correct, verify, or validate actions effectively.

    21 CFR 820.100
  5. Smiths Medical did not adequately receive, review, and evaluate complaints, including missing investigation records and incorrect hazard codes.

    21 CFR 820.198(a)
  6. Smiths Medical did not maintain a complete design history file for the Medfusion 4000 because at least five Letters to File were not retained.

    21 CFR 820.30(j)

What FDA wants

FDA tells Smiths Medical to notify the agency in writing within 15 business days of the specific steps taken to correct the violations and prevent recurrence, including corrective action documentation and a timetable for actions that will take longer.

Who should pay attention

  • hospitals and clinicians using Medfusion infusion pumps
  • distributors and service organizations for infusion pumps
  • other makers of software-controlled infusion pumps

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  2. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  3. O.N. Diagnostics, LLC

    FDA says O.N. Diagnostics sold changed VirtuOst VFA software without required clearance and had quality and reporting failures.

    High risk
  4. Lion Street Medical, d/b/a Pensar Medical LLC

    FDA warns Pensar Medical over unreported wound-therapy injuries and missing device reporting procedures.

    High risk